

Resource Summary Report

Generated by [kravitz2](#) on Aug 1, 2026

Vall d'Hebron Institute of Oncology; Barcelona; Spain

RRID:SCR_011755

Type: Tool

Proper Citation

Vall d'Hebron Institute of Oncology; Barcelona; Spain (RRID:SCR_011755)

Resource Information

URL: <http://www.vhio.net/>

Proper Citation: Vall d'Hebron Institute of Oncology; Barcelona; Spain (RRID:SCR_011755)

Description: A center of biomedical research with scientists and physicians working together at the nexus of basic science and clinical research related to oncological diseases. They also pursue to make contributions to the development of new and better therapies for the treatment of cancer. * Scientific practice into the clinic for the benefit of oncology patients * Scientific research excellence in the areas of basic, translational and clinical research * Scientific cooperation among national and international oncology research institutions * Promotion of all oncology research-related activities, thereby contributing towards improving the quality of life of people

Abbreviations: VHIO

Synonyms: Vall d'Hebron Institute of Oncology

Resource Type: institution

Resource Name: Vall d'Hebron Institute of Oncology; Barcelona; Spain

Resource ID: SCR_011755

Alternate IDs: nlx_158353

Record Creation Time: 20220129T080306+0000

Record Last Update: 20260725T190719+0000

Ratings and Alerts

No rating or validation information has been found for Vall d'Hebron Institute of Oncology; Barcelona; Spain.

No alerts have been found for Vall d'Hebron Institute of Oncology; Barcelona; Spain.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Raju A, et al. (2025) Comprehensive Cytokine Gene Expression and Multiplex Analysis in Breast Cancer Patients: Insights Into Immune Profiles and Prognostic Factors' Association. Cureus, 17(6), e85288.

Capdevila J, et al. (2025) Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914). Clinical cancer research : an official journal of the American Association for Cancer Research, 31(22), 4655.